All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Immunomedics Inc.'s epratuzumab exceeded expectations in a Phase II trial in follicular lymphoma, producing a response rate of 88.2 percent when used in combination with rituximab.
